The results presented herein show that exogenous delivery of a pharmaceutical-grade version of NRG/GGF2 not only improves post-MI cardiac function but may also promote better intercostal skeletal muscle function via shifting the balance of stem-cell derived differentiated cell types. Here, NRG1 is linked to myocardial infarction.